N/A
Manufactured by Advanz Pharma (US) Corp.
7,486 FDA adverse event reports analyzed
Last updated: 2026-04-15
PILOCARPINE HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Advanz Pharma (US) Corp.. The most commonly reported adverse reactions for PILOCARPINE HYDROCHLORIDE include DRUG INEFFECTIVE, HEADACHE, VISION BLURRED, NAUSEA, VISUAL IMPAIRMENT. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for PILOCARPINE HYDROCHLORIDE.
Out of 3,206 classified reports for PILOCARPINE HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 7,486 FDA FAERS reports that mention PILOCARPINE HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, HEADACHE, VISION BLURRED, NAUSEA, VISUAL IMPAIRMENT, PAIN. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Advanz Pharma (US) Corp. in connection with PILOCARPINE HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.